Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. News about FATE centers on its off-the-shelf CAR T-cell and NK-cell product candidates, including FT819, FT836 and FT839, and on clinical or preclinical data presented at medical and cell-therapy meetings.
Recurring updates cover FT819 in systemic lupus erythematosus and other autoimmune diseases, next-generation CAR T programs for hematological malignancies and solid tumors, manufacturing and FDA CMC interactions, Regenerative Medicine Advanced Therapy designation, investor-conference participation, financial results, and Nasdaq employee inducement equity awards.
Fate Therapeutics (NASDAQ:FATE) reported first quarter 2026 results and pipeline progress. Revenue was $1.3 million, with total operating expenses of $34.3 million, and cash, cash equivalents and investments of $174.8 million, extending operating runway into 2028.
The company plans to start RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 in refractory SLE with lupus nephritis in 2H 2026, while advancing FT819, FT839 and FT836 clinical programs and benefiting from FDA CDRP and RMAT designations.
Fate Therapeutics (NASDAQ:FATE) is presenting new data on its off-the-shelf CAR T-cell therapies FT819, FT839, and FT836 at the 2026 ASGCT meeting.
FT819 Phase 1 SLE data show clinical responses without conditioning chemotherapy; FT839 and FT836 preclinical results demonstrate broad immune-cell targeting and tumor control with Sword and Shield™ engineering.
Fate Therapeutics (NASDAQ: FATE) said the FDA selected its off-the-shelf iPSC-derived anti-CD19 CAR T candidate FT819 for the CMC Development and Readiness Pilot (CDRP) program to support manufacturing readiness for SLE with lupus nephritis.
Selection and existing RMAT designation aim to accelerate CMC engagement and help align manufacturing readiness with a planned Phase 2 potentially registrational trial.
Fate Therapeutics (NASDAQ: FATE) will present clinical and preclinical data from its off-the-shelf CAR T-cell pipeline at the 2026 ASGCT Annual Meeting in Boston, May 11–15, 2026. Presentations cover FT819 SLE data without conditioning chemotherapy, an oral on dual-targeting FT839, and preclinical FT836 MICA/B tumor data.
Key sessions: FT819 poster May 12, FT836 poster May 13, and FT839 oral May 14. The programs focus on iPSC-derived, off-the-shelf CAR T approaches for autoimmune and oncology indications.
Fate Therapeutics (NASDAQ: FATE) granted 30,200 restricted stock units (RSUs) on May 1, 2026 to one newly hired non-executive employee as an inducement under its Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The grant was approved by the Compensation Committee. The RSUs vest over four years, with 25% vesting on each anniversary of the grant date, subject to continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE) will present clinical data for its off-the-shelf CAR T candidate FT819 at CCR–East 2026 (Destin, FL; Apr 30–May 3, 2026).
Presentation covers safety, efficacy, and translational results from 13 SLE patients (data cutoff Dec 23, 2025), including SLEDAI-2K −13 points at Month 6 and substantial FACIT-Fatigue improvements after a single FT819 dose with reduced conditioning.
Fate Therapeutics (NASDAQ: FATE) will present preclinical data for its next‑generation off‑the‑shelf CAR T candidate FT839 at the AACR Annual Meeting, April 17–22, 2026 in San Diego.
FT839 is described as a 13‑point edited, dual‑CAR product targeting CD19 and CD38, using Sword and Shield™ technology to evade host immune responses and potentially remove the need for conditioning chemotherapy. Poster: April 21, 2026, 9:00 a.m.–Noon PDT.
Fate Therapeutics (NASDAQ: FATE) said management will participate in five investor conferences in Q2 2026 with scheduled dates and locations listed below.
- April 14 — Needham Virtual Healthcare Conference (virtual)
- May 13 — Bank of America Healthcare Conference, Las Vegas
- May 19 — H.C. Wainwright BioConnect, New York
- June 4 — Jefferies Global Healthcare, New York
- June 10 — Goldman Sachs Global Healthcare, Miami Beach
The company said presentations or fireside chats may occur and live webcasts will be available under Events & Presentations on the company website, with archived replays accessible for 30 days.
Fate Therapeutics (NASDAQ: FATE) granted 7,260 restricted stock units (RSUs) on April 1, 2026 to one newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved the award under the companys Amended and Restated Inducement Equity Plan.
The RSUs vest over four years with 25% vesting on each anniversary, subject to continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE) granted restricted stock units representing 50,700 shares to three newly hired non-executive employees on March 2, 2026 as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The awards vest over four years with 25% vesting on each anniversary, subject to continued employment.